3D Biology: The paradigm shift in next-generation drug discovery [Interactive infographic]
- April 19, 2023
- 3D Biology Team
The drug discovery landscape is changing.
Bringing a drug to market has historically been time-consuming and costly, with many candidates failing in the first phase of clinical trials. Growing evidence suggests that screening compounds early in the process using traditional models – like animals, and cell cultures propagated in 2D – may be a contributing factor. Researchers are now navigating toward complex, human-relevant 3D systems like organoids, as they are believed to better represent how the body might respond to treatment.
Here we dive deeper into why the industry is embracing organoids for next-gen drug discovery and showcase the innovations supporting scientists in their 3D biology journey.
Has this inspired you to explore a transition from 2D to 3D biology? To find solutions for your organoid challenges? Or to scale the work you’re already doing?
Our experts can help. Reach out to us today to get started.
The role of CRISPR in microbiome engineering [Podcast]
The Role of CRISPR in Scientific Breakthroughs in Microbiome Engineering…
SLAS 2023 snapshot: innovations, learnings, and what you may have missed
We caught up with Laura Dranschak, Director of Commercial Operations…
Advantages of ELISA for Accurate and Accelerated Drug Discovery [Podcast]
Since its discovery nearly 50 years ago, the Enzyme-Linked Immunosorbent…
How 3D Cell Models Will Shape the Future of Drug Discovery
Target discovery and drug development rely heavily on 2D cell and animal…
A case study for assay-ready patient-derived organoids (PDOs) and high-throughput 3D imaging to advance drug discovery
Introduction – the problem. The average cost of bringing a new drug to…